Voyager Therapeutics, Inc. (VYGR)
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
$3.25-4.41%
Close 2026-09-09 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-09
Warn: Management is running behind on a stated commitment.
Voyager plans to start a key Alzheimer's trial in 2026. It has strong partnerships to help growth. The company aims to have enough cash through 2028. Recent earnings beats show some progress.
Voyager is still losing money and burning cash fast. Cash concerns could hurt its ability to fund trials. Key officers have left recently, which may slow progress.
The price is about 52% below our fair value near $8. Analysts expect 35% revenue growth, but losses continue. The market partly prices in risks from cash burn and losses.
Breaks if: Cash runs out before end of 2028
Maintain sufficient cash, cash equivalents, and marketable securities, along with collaboration reimbursements and interest income, to fund operating expenses and capital expenditures into 2028.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. VYGR is in the biotech sector, which can be volatile and is currently facing elevated risks, but it has potential upside if management executes well on its clinical trials and partnerships.
The market appears to price VYGR as cheap compared to its peers, with a significant expectations gap. However, the valuation is justified given the company's current loss-making status and the mixed recent performance.
Management has stable priorities, including advancing clinical trials and ensuring cash sufficiency. However, the company is experiencing ongoing cash burn and declining collaboration revenue, which may affect its financial health in the near term.
The long-term thesis hinges on key factors such as the success of the VY1706 clinical trial for Alzheimer's and the performance of sector bellwethers like VRTX and REGN. Additionally, any cuts to guidance or worsening economic indicators could negatively impact investor sentiment.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified that could weaken the thesis.
as of 2026-09-09
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 4 of last 4 quarters. Cash and equivalents declined from $171.7M in 2026-Q1 to $148.8M in 2026-Q2 but management consistently expects this liquidity plus collaboration reimbursements and interest income to fund operations and capex into 2028. The trajectory shows ongoing cash burn but aligns with stated runway.
“Cash and equivalents expected to fund operations and capex into 2028”
“Cash position expected to provide runway into 2028”
“Cash expected to be sufficient to meet operating expenses and capex into 2028”
“Cash expected to be sufficient to meet operating expenses and capex into 2028”
Breaks if: Trial not started by end of 2026
Breaks if: No new partnerships or loss of key partners
In the next 1 to 3 years, VYGR's performance will depend on its ability to execute on clinical trials and manage cash flow effectively. Not investment advice.